Whole-body FDG-PET imaging in the management of patients with cancer

Seminars in Nuclear Medicine

Volumn 32, Issue 1, 2002, Pages 35-46

  Hustinx, Roland ^a,b,c   Bénard, François ^a,b,c   Alavi, Abass ^a,b,c,d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CARCINOMA; GYNECOLOGIC CANCER; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; THYROID CARCINOMA; WHOLE BODY TOMOGRAPHY;

EID: 0036156598     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.29272     Document Type: Article

References (136)

1. Analytical decision model for the cost-effective management of solitary pulmonary nodules
2. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis
3. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis
4. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT
5. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer
6. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases?
7. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions
8. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
9. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography
10. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases
11. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
12. Detection of extrathoracic metastases by positron emission tomography in lung cancer
13. Staging non-small cell lung cancer with whole-body PET
14. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
15. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases
16. Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) provides high impact and powerful prognostic stratification in staging new diagnosed non-small cell lung cancer
17. The utility of F-18 FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification
18. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma
19. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis
20. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan
21. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: Priority for a PET-based strategy after nodal-negative CT results
22. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
23. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease
24. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer
25. Whole body positron emission tomography in the treatment of Hodgkin disease
26. 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial
27. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging
28. Extranodal malignant lymphoma: Detection with FDG PET versus CT
29. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
30. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
31. Primary staging of lymphomas: Cost-effectiveness of FDG-PET versus computed tomography
32. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow
33. Detection of lymphoma in bone marrow by whole-body positron emission tomography
34. Positron emission tomography for staging low-grade non Hodgkin's lymphomas
35. The impact of FDG positron emission tomography imaging on the management of lymphomas
36. The role of positron emission tomography (PET) in the management of lymphoma patients
37. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
38. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
39. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma
40. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
41. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
42. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
43. Persistent tumor 18f-fdg uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma
44. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?
45. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer
46. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
47. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum
48. Impact of (18)f-fdg pet on managing patients with colorectal cancer: The referring physician's perspective
49. Liver resection for colorectal metastases
50. Liver resection for metastatic colorectal cancer: Assessing the risk of occult irresectable disease
51. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
52. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
53. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
54. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study
55. PET scanning in malignancy: Infant, adolescent or mature citizen?
56. Decision analysis for the cost-effective management of recurrent colorectal cancer
57. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
58. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer. The utility of positron emission tomography (PET)
59. Improvement in staging of esophageal cancer with the addition of positron emission tomography
60. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography
61. Role of positron emission tomography in staging esophageal cancer
62. Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma
63. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography
64. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma
65. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography
66. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer
67. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation
68. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US
69. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer
70. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma
71. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: Diagnostic limitations
72. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease
73. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses
74. Detection of liver metastases from pancreatic cancer using FDG PET
75. Contribution of PET in the detection of liver metastases from pancreatic tumours
76. 18-Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer
77. FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study
78. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET
79. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients
80. A review of the literature for whole-body FDG PET in the management of patients with melanoma
81. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma
82. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy
83. Positron emission tomography in the detection and management of metastatic melanoma
84. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma
85. Positron emission tomography scanning in malignant melanoma
86. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
87. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers
88. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer
89. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
90. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography
91. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI
92. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer
93. Evaluation of head and neck cancer with 18F-FDG PET: A comparison with conventional methods
94. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?
95. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses
96. Head and neck cancer: Detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose
97. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient
98. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography
99. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography
100. Detection of unknown occult primary tumors using positron emission tomography
101. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)
102. Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose
103. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors
104. FDG PET detection of unknown primary tumors
105. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer
106. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study
107. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer
108. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels
109. Comparison of (18)FFDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma
110. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes
111. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans
112. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography
113. Value of FDG PET in papillary thyroid carcinoma with negative 1311 whole-body scan
114. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels
115. FDG PET of recurrent or metastatic 1311-negative papillary thyroid carcinoma
116. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan
117. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
118. Diagnostic value of positron emission tomography for detecting breast cancer
119. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours
120. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose
121. Qualitative [18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
122. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations
123. Glucose metabolism of breast cancer assessed by 18F-FDG PET: Histologic and immunohistochemical tissue analysis
124. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
125. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
126. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
127. Value of 18fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma
128. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures
129. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography
130. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
131. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience
132. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
133. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
134. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
135. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
136. PET scans and technology assessment: Deja vu?